Arbutus Biopharma Corporation (ABUS)

[mick]

$ABUS
Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Nov. 19, 2021 7:29 PM ET
Arbutus Biopharma Corporation (ABUS)
ARWR, ASMB, DRNA,JNJ,MRNA,NONOF,NVO,VACC
40 Comments
5 Likes
Summary
Recent Acquisition of RNAi drug maker Dicerna by Novo Nordisk makes a case for eventual partnership/buyout of Arbutus Biopharma.
AB-729 has proven to work in treating patients with Hepatitis B with significant Hepatitis B surface antigen reduction alone. Four triple combinations studies have started or will be initiated soon.
The global Hepatitis B Virus market is expected to reach $35.63 billion in 2030.
Patent dispute ongoing over Moderna's Covid-19 Vaccine. Favorable ruling in favor of Arbutus from Federal Appeals Court would be huge news for the company as it relates to its patents for lipid nanoparticles.
This idea was discussed in more depth with members of my private investing community, Biotech Analysis Central. Learn More »